Objective: Despite the low local toxicity of the used agents, Cisplatin-based chemotherapy (CBP) for patients with testicular germ cell tumors (TGCT) is mostly delivered via a central venous access (CVA). Since 2008, CBP is given peripherally in our hospital. Methods: Medical reports of TGCT patients who received CBP between September 1991 and August 2014 were evaluated. Complications regarding the way of administration (CVA vs. peripheral venous catheter [PVC]) were classified according to the Common Terminology Criteria of Adverse Events. The complication rates were compared using chi square test and propensity score matching. Results: During 288 cycles in 109 patients, 85 complications (29.5%) were observed with similar rates for overall (PVC 31.3%, CVA 29.9%; p = 0.820) and grade I complications (21.3%, 25.4%; p = 0.470). More grade II complications were observed in the PVC group (10.0 vs. 1.5%; p < 0.001). Grade III complications requiring invasive treatment were found only in the CVA group (3.0%; p = 0.120). Using propensity score matching, no differences in overall (p = 0.950), grade I (p = 0.540) and grades II/III (p = 0.590) complications were seen. Conclusion: The peripheral and central administration of CBP has similar overall complication rates. Despite more grade II complications, the peripheral administration of CBP is a safe alternative for TGCT patients. Additionally, no severe grade III complications occurred.

Keywords:
Chemotherapy, Testicular cancer, Peripheral administration, Central administration
1.
Bleyer A, Viny A, Barr R: Cancer in 15- to 29-year-olds by primary site. Oncologist 2006;11:590-601.
2.
Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, et al: NORDCAN - a Nordic tool for cancer information, planning, quality control and research. Acta Oncol 2010;49:725-736.
3.
Einhorn LH, Donohue J: Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977;87:293-298.
4.
La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al: Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010;21:1323-1360.
5.
Stang A, Bray F, Dieckmann KP, Lortet-Tieulent J, Rusner C: Mortality of testicular cancer in east and west Germany 20 years after reunification: a gap not closed yet. Urol Int 2015;95:160-166.
6.
de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, et al: Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19:1629-1640.
7.
Fosså SD, de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, et al: Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 2003;21:1107-1118.
8.
Singhera M, Lees K, Huddart R, Horwich A: Minimizing toxicity in early-stage testicular cancer treatment. Expert Rev Anticancer Ther 2012;12:185-193.
9.
Krege S: [PEB treatment of testicular cancer]. Aktuelle Urol 2012;43:342-345.
10.
Suzuki K, Yumura Y, Ogawa T, Saito K, Kinoshita Y, Noguchi K: Regeneration of spermatogenesis after testicular cancer chemotherapy. Urol Int 2013;91:445-450.
11.
Laguna MP, Pizzocaro G, Klepp O, Algaba F, Kisbenedek L, Leiva O: EAU guidelines on testicular cancer. Eur Urol 2001;40:102-110.
12.
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al: EAU guidelines on testicular cancer: 2011 update. Eur Urol 2011;60:304-319.
13.
de Wit M, Ortner P, Lipp HP, Sehouli J, Untch M, Ruhnke M, et al: Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment. Onkologie 2013;36:127-135.
14.
Fields S, Koeller J, Topper RL, Guritz G, Von Hoff D: Local soft tissue toxicity following cisplatin extravasation. J Natl Cancer Inst 1990;82:1649-1650.
15.
Bairey O, Bishara J, Stahl B, Shaklai M: Severe tissue necrosis after cisplatin extravasation at low concentration: possible ‘immediate recall phenomenon'. J Natl Cancer Inst 1997;89:1233-1234.
16.
Preuss P, Partoft S: Cytostatic extravasations. Ann Plast Surg 1987;19:323-329.
17.
Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 1990;4:41-60.
18.
Hecker JF: Survival of intravenous chemotherapy infusion sites. Br J Cancer 1990;62:660-662.
19.
Mateu J, Alzamora M, Franco M, Buisán MJ: Ifosfamide extravasation. Ann Pharmacother 1994;28:1243-1244.
20.
Austin PC: An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424.
21.
Langstein HN, Duman H, Seelig D, Butler CE, Evans GR: Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 2002;49:369-374.
22.
Olver IN, Aisner J, Hament A, Buchanan L, Bishop JF, Kaplan RS: A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 1988;6:1732-1735.
23.
Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995;13:2851-2855.
24.
Nayeemuddin M, Pherwani AD, Asquith JR: Imaging and management of complications of central venous catheters. Clin Radiol 2013;68:529-544.
25.
Boersma RS, Jie KS, Verbon A, van Pampus EC, Schouten HC: Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann Oncol 2008;19:433-442.
26.
Lee AY, Kamphuisen PW: Epidemiology and prevention of catheter-related thrombosis in patients with cancer. J Thromb Haemost 2012;10:1491-1499.
27.
Verso M, Agnelli G: Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:3665-3675.
28.
Linnemann B, Lindhoff-Last E: [Management of catheter-related upper extremity deep vein thrombosis]. Zentralbl Chir 2013;138(suppl 2):e86-e94.
29.
Okada S, Shiraishi A, Yamashiro Y, Inoue T, Tsuge D, Aida M, et al: A retrospective statistical analysis of the late complications associated with central venous port placements. Jpn J Radiol 2015;33:21-25.
30.
Berardi R, Rinaldi S, Santini D, Vincenzi B, Giampieri R, Maccaroni E, et al: Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. Support Care Cancer 2015;23:1295-1302.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.